Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Yip, Hon Kan ^a   Tsai, Tzu Hsien ^a   Lin, Hung Sheng ^a   Chen, Shu Fang ^a   Sun, Cheuk Kwan ^a   Leu, Steve ^a   Yuen, Chun Man ^a   Tan, Teng Yeow ^a   Lan, Min Yu ^a   Liou, Chia Wei ^a   Lu, Cheng Hsien ^a   Chang, Wen Neng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CD31 ANTIGEN; CD34 ANTIGEN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN RECEPTOR 2; ANTIANEMIC AGENT; BIOLOGICAL MARKER; ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; DRUG HYPERSENSITIVITY; ENDOTHELIAL PROGENITOR CELL; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; POLYCYTHEMIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE PATIENT; THROMBOSIS; TREATMENT OUTCOME; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; STEM CELL; STROKE; TIME;

AGED; BIOLOGICAL MARKERS; ENDOTHELIAL CELLS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; STEM CELLS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79251585247     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10002     Document Type: Article

References (46)

1. Hankey GJ. Stroke: how large a public health problem, and how can the neurologist help?. Arch Neurol 1999, 56:748-754. 10.1001/archneur.56.6.748, 10369318.
2. World Health Organization World Health Report 1999 - Making a Difference 1999, Geneva, Switzerland: World Health Organization, World Health Organization.
3. Association AH. Stroke Statistics 2002, Dallas, Dallas, TX: American Heart Association.
4. Muir KW, Weir CJ, Murray GD, Povey C, Lees KR. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke 1996, 27:1817-1820.
5. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
6. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R. Indications for early aspirin use in acute ischemic stroke A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000, 31:1240-1249.
7. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001, 32:2559-2566. 10.1161/hs1101.098524, 11692017.
8. Yip HK, Liou CW, Chang HW, Lan MY, Liu JS, Chen MC. Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 2005, 20:120-128. 10.1159/000086802, 16006760.
9. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009, CD000213.
10. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007, 369:275-282. 10.1016/S0140-6736(07)60149-4, 17258667.
11. Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007, 38:1655-1711. 10.1161/STROKEAHA.107.181486, 17431204.
12. Bravata DM. Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice. CNS Drugs 2005, 19:295-302. 10.2165/00023210-200519040-00002, 15813643.
13. Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, Lewis S, Lindley R, Neilson A, Wardlaw J. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Stroke 2004, 35:1490-1497. 10.1161/01.STR.0000126871.98801.6E, 15105519.
14. Thomalla G, Sobesky J, Kohrmann M, Fiebach JB, Fiehler J, Zaro Weber O, Kruetzelmann A, Kucinski T, Rosenkranz M, Rother J, Schellinger PD. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 2007, 38:313-318. 10.1161/01.STR.0000254565.51807.22, 17204683.
15. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003, 100:4802-4806. 10.1073/pnas.0630444100, 153636, 12663857.
16. Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M, Tsukamoto O, Okada K, Koyama H, Komamura K, Takashima S, Shinozaki Y, Mori H, Shiraga M, Kitakaze M, Hori M. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006, 48:176-184. 10.1016/j.jacc.2006.04.008, 16814664.
17. Nakamura R, Takahashi A, Yamada T, Miyai N, Irie H, Kinoshita N, Sawada T, Azuma A, Matsubara H. Erythropoietin in patients with acute coronary syndrome and its cardioprotective action after percutaneous coronary intervention. Circ J 2009, 73:1920-1926. 10.1253/circj.CJ-09-0219, 19690392.
18. Hasselblatt M, Ehrenreich H, Siren AL. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J Neurosurg Anesthesiol 2006, 18:132-138. 10.1097/00008506-200604000-00007, 16628067.
19. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 2009, 111:171-180. 10.3171/2009.3.JNS081332, 19344224.
20. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jahnig P, Herrmann M, Knauth M, Bahr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009, 40:e647-656. 10.1161/STROKEAHA.109.564872, 19834012.
21. van der Meer P, Voors AA, Lipsic E, van Gilst WH, van Veldhuisen DJ. Erythropoietin in cardiovascular diseases. Eur Heart J 2004, 25:285-291. 10.1016/j.ehj.2003.11.017, 14984916.
22. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM, van Veldhuisen DJ, van Gilst WH, Schoemaker RG. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004, 44:473-479. 10.1097/01.fjc.0000140209.04675.c3, 15454856.
23. Lin JS, Chen YS, Chiang HS, Ma MC. Hypoxic preconditioning protects rat hearts against ischaemia-reperfusion injury: role of erythropoietin on progenitor cell mobilization. J Physiol 2008, 586:5757-5769. 10.1113/jphysiol.2008.160887, 2655408, 18845609.
24. Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, Liu JS, Youssef AA, Chang HW. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 2008, 39:69-74. 10.1161/STROKEAHA.107.489401, 18063830.
25. Goldstein LB, Bertels C, Davis JN. Interrater reliability of the NIH stroke scale. Arch Neurol 1989, 46:660-662.
26. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md State Med J 1965, 14:61-65.
27. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988, 19:604-607.
28. Lambiase PD, Edwards RJ, Anthopoulos P, Rahman S, Meng YG, Bucknall CA, Redwood SR, Pearson JD, Marber MS. Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation 2004, 109:2986-2992. 10.1161/01.CIR.0000130639.97284.EC, 15184289.
29. Rustemeyer P, Wittkowski W, Greve B, Stehling M. Flow-cytometric identification, enumeration, purification, and expansion of CD133+ and VEGF-R2+ endothelial progenitor cells from peripheral blood. J Immunoassay Immunochem 2007, 28:13-23. 10.1080/15321810601025549, 17236393.
30. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999, 85:221-228.
31. Wang CH, Verma S, Hsieh IC, Chen YJ, Kuo LT, Yang NI, Wang SY, Wu MY, Hsu CM, Cheng CW, Cherng WJ. Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J Mol Cell Cardiol 2006, 41:34-43. 10.1016/j.yjmcc.2006.03.006, 16678199.
32. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De Ferrari GM, Ferlini M, Goffredo L, Bertoletti A, Klersy C, Pecci A, Moratti R, Tavazzi L. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005, 105:199-206. 10.1182/blood-2004-05-1831, 15345590.
33. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999, 5:434-438. 10.1038/8462, 10202935.
34. Luttun A, Carmeliet G, Carmeliet P. Vascular progenitors: from biology to treatment. Trends Cardiovasc Med 2002, 12:88-96. 10.1016/S1050-1738(01)00152-9, 11852257.
35. Taguchi A, Matsuyama T, Moriwaki H, Hayashi T, Hayashida K, Nagatsuka K, Todo K, Mori K, Stern DM, Soma T, Naritomi H. Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation 2004, 109:2972-2975. 10.1161/01.CIR.0000133311.25587.DE, 15184275.
36. Minnerup J, Heidrich J, Rogalewski A, Schabitz WR, Wellmann J. The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 2009, 40:3113-3120. 10.1161/STROKEAHA.109.555789, 19542052.
37. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000, 97:10526-10531. 10.1073/pnas.97.19.10526, 27058, 10984541.
38. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003, 198:971-975. 10.1084/jem.20021067, 2194205, 12975460.
39. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001, 412:641-647. 10.1038/35088074, 11493922.
40. Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M. Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 2001, 276:39469-39475. 10.1074/jbc.M105832200, 11504731.
41. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002, 8:495-505. 2040012, 12435860.
42. Spence JD. Treating hypertension in acute ischemic stroke. Hypertension 2009, 54:702-703. 10.1161/HYPERTENSIONAHA.109.134486, 19652079.
43. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002, 33:1315-1320. 10.1161/01.STR.0000014509.11540.66, 11988609.
44. Sare GM, Ali M, Shuaib A, Bath PM. Relationship between hyperacute blood pressure and outcome after ischemic stroke: data from the VISTA collaboration. Stroke 2009, 40:2098-2103. 10.1161/STROKEAHA.108.539155, 19359649.
45. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009, 29:424-430. 10.1161/ATVBAHA.108.181735, 19122170.
46. Besler C, Heinrich K, Riwanto M, Luscher TF, Landmesser U. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des 2010, 16:1480-1493. 10.2174/138161210791051013, 20196740.